CClinicalTrials.gg
CompletedNCT02403089NEOMAITUpdated Feb 3, 2023

Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients

An observational study in Term and Preterm Neonates (24-41 Weeks Gestational Age) and Hematopoietic Stem Cell Transplant Recipient Children, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2023-02-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
1 Day to 18 Years
Sex
All
01

Study summary

The objective of this study is 1/ to determine the rate and kinetics of MAIT cell expansion and maturation in neonates in relation with gestational age, and in HSCT recipient children in relation with the source of donor stem cells, 2/ to correlate gut microbiota diversity and function with MAIT cell maturation and function in neonates and HSCT recipients; and 3/ to link MAIT cells and gut microbiota composition with microbial infections and severe intestinal inflammatory events in term and preterm neonates, and in HSCT recipients

Read the detailed description

The mucosa-associated invariant T (MAIT) cells are innate-like T cells with restricted T cell receptor (TCR) usage, which are preferentially localized in mucosal tissues and respond to microbial infection by rapidly producing cytokines and cytotoxic effectors. They recognize the non-classical related molecule (MR1). MAIT cells react against a newly identified class of antigens presented by MR1: Riboflavin (Rib) precursors, which are found in most bacteria and yeasts. Currently, very little is known about the ontogeny of MAIT cells in the human, because of the difficulty to follow longitudinally their development. Cross-sectional studies have identified only the initial (cord blood) and final (adult subjects) steps of human MAIT cell maturation program. Moreover, there are no data on relationships between human MAIT cell expansion and maturation, and gut microbiota development. Given the potential importance of MAIT cells in protection from microbial infections at epithelial surfaces, we will investigate the maturation dynamics of MAIT cells in relation with gut microbiota diversity and function in two clinical settings characterized by a high predisposition to severe microbial infections before the establishment of protective adaptive immunity, namely i/ the neonatal period and ii/ the early immune reconstitution period following allogeneic hematopoietic stem cell transplantation (HSCT) in children. Our study will combine multiparametric phenotypic and functional characterization of MAIT cells with the use of new molecular microbiota analytic methodology (high throughput sequencing, metagenomics, Rib microbiology) to determine how the presence or functionality of MAIT cells is influenced by the gut microbiota.

Our consortium is composed of three independent research teams, experts in innate immunity, microbial ecology and MAIT cell biology, three independent clinical teams providing exceptional resources to patient samples, and one team providing expertise for methodology and statistical analysis. Their synergistic interaction will offer the various complementary expertise that is necessary for this project.

This project will decipher how MAIT cell numbers or functions are influenced by the gut microbiota composition, and reciprocally, how MAIT cells regulate or control expansion of gut microbiota components competing with opportunistic or pathogenic bacteria or responsible for infections. Ultimately, this study will determine how and when gut microbiota and MAIT cell interactions are involved in the control of severe infectious or intestinal inflammatory events in high risk infants, an indispensable step to design predictive biomarkers and ultimately propose new therapeutic options.

02

Conditions studied

  • Term and Preterm Neonates (24-41 Weeks Gestational Age)
  • Hematopoietic Stem Cell Transplant Recipient Children

Browse trials for

Keywords

  • MAIT (Mucosal-Associated Invariant T) cells
  • Gut microbiota
  • Preterm birth
  • Hematopoietic stem cell transplantation
  • Microbial infections
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 300 is above the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

newborns hospitalized in the Neonatal Intensive Care Unit of the Hospital Robert Debré and grafted children hospitalized in the Hematology-Immunology Pediatric Service of the Hospital Robert Debré

Inclusion criteria

  • neonates 24-41 weeks gestational age
  • hematopoietic stem cell transplant recipient children (\< 18 years old, donor source: cord blood or genoidentical donor)

Exclusion criteria

Exclusion Criteria:

  • neonates : chromosomal abnormalities detected before birth
  • source of HSCT: phenol-identical donors
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • neonates

    neonates 24-41 weeks gestational age

    Other: Tubes fund recovery blood count

  • children

    hematopoietic stem cell transplant recipient children (\< 18 years old, donor source: cord blood or genoidentical donor)

    Other: the rest of the blood test and stool sample

Interventions

  • OtherTubes fund recovery blood count

    Tubes fund recovery of blood counts among newborns

  • Otherthe rest of the blood test and stool sample

    blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.

06

What researchers measure

Primary outcomes

  1. MAIT cell numbering neonates after birth

    Absolute number, percentage and phenotype of MAIT cells by flow cytometry in the circulating blood after birth according to gestational age and / or maternal-fetal infections (IMF), or after allogeneic HSCT according to the origin of HSCs.

    Time frame: to 60days

Secondary outcomes

  1. Absolute number of MAIT

    Absolute number and percentage of MAIT among mothers of infants on the day of delivery and in geno-identical donors before transplantation.

    Time frame: to 60days

  2. Absolute number of other immune cell populations

    Absolute number and percentage of other immune cell populations by flow cytometry on the same blood samples.

    Time frame: to 60 days

07

Study locations

1 site
  • Hôpital Robert Debré
    Paris, 75019, France
08

References and documents

Publications

  • Ben Youssef G, Tourret M, Salou M, Ghazarian L, Houdouin V, Mondot S, Mburu Y, Lambert M, Azarnoush S, Diana JS, Virlouvet AL, Peuchmaur M, Schmitz T, Dalle JH, Lantz O, Biran V, Caillat-Zucman S. Ontogeny of human mucosal-associated invariant T cells and related T cell subsets. J Exp Med. 2018 Feb 5;215(2):459-479. doi: 10.1084/jem.20171739. Epub 2018 Jan 16. PubMed 29339446 ↗
  • Tourret M, Talvard-Balland N, Lambert M, Ben Youssef G, Chevalier MF, Bohineust A, Yvorra T, Morin F, Azarnoush S, Lantz O, Dalle JH, Caillat-Zucman S. Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. J Immunother Cancer. 2021 Oct;9(10):e003123. doi: 10.1136/jitc-2021-003123. PubMed 34615705 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02403089
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Institut Curie
Responsible party
Sponsor
First posted
Mar 31, 2015
Start date
Mar 2015
Primary completion
Feb 2018
Completion
Feb 2018
Last update
Feb 3, 2023

Study contacts

Biran Valérie, PHD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion